Hi gingerclam,Along the same lines of your thinking… on the Acadia results call in the Q&A, when Serge was asked about the potential for trofinetide to address other indications, (time: 52:30) you’d think given the successful results, there might be at least a hint of optimism here. Instead, he fluffed around, mentioned TBI, ultimately agreed yes but finished with … it’s a little premature to go there and we’re focused on Retts getting it to FDA approval. Maybe he’s just a straight shooter but no mention of Fragile X had me wondering his agenda. Keeping Neuren affordable?
-
- There are more pages in this discussion • 796 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.03 |
Change
0.180(1.40%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $13.15 | $13.15 | $12.92 | $1.110M | 85.08K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 33 | $13.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.04 | 406 | 3 |
View Market Depth
| Last trade - 10.16am 18/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |